Patents by Inventor Yeoun Jin Kim

Yeoun Jin Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKERS FOR DETECTION OF LUNG CANCER
    Publication number: 20230213521
    Abstract: The application discloses in vitro methods for diagnosing lung cancer in a subject, wherein the method comprises detecting at least one biomarker selected from the group consisting of Rho GDP dissociation inhibitor beta (ARHGDIB), alpha-tubulin 4A (TUBA4A), glutathione S-transferase omega 1 (GSTO1), filamin A (FLNA), peroxiredoxin 6 (PRDX6) and cadherin 13 (CDH13) in a biological sample from the subject, and kits for measuring said at least one biomarker.
    Type: Application
    Filed: April 28, 2021
    Publication date: July 6, 2023
    Applicants: Luxembourg Institute of Health (LIH), Fred Hutchinson Cancer Center, The Translational Genomics Research Institute (TGEN)
    Inventors: Victoria EL KHOURY, Anna Elisabeth SCHRITZ, Yeoun Jin KIM, Guy BERCHEM, Amanda PAULOVICH, Jeffrey WHITEAKER, Konstantinos PETRITIS, Patrick PIRROTTE, Tony TEGELER
  • p16 EXPRESSION AND CANCER TREATMENT OUTCOME
    Publication number: 20190219582
    Abstract: Methods are provided for identifying whether colorectal cancer (CRC) will be responsive to treatment with the combination of the therapeutic agents cisplatin and pemetrexed. Specified p16 fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in formalin-fixed tissue sample that was obtained from the cancer patient and compared to a p16 reference level in order to determine if the CRC patient will positively respond to treatment with the combination of cisplatin and pemetrexed therapeutic agents.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 18, 2019
    Inventors: Fabiola Cecchi, Todd Hembrough, Yeoun Jin Kim
  • METHODS FOR TREATING SARCOMA
    Publication number: 20190167628
    Abstract: Molecular markers of response to various chemotherapies were measured in tumor samples of 5 sarcoma subtypes to identify effective treatment regimens based on expression of chemotherapy biomarkers. The molecular profiles for rhabdomyosarcoma support the use of standard-of-care treatment, while other profiles showed that alternative agents differing from standard-of-care will be effective, including gemcitabine (osteosarcoma), taxane (leiomyosarcoma, Ewing's sarcoma), and platinum (leiomyosarcoma, liposarcoma, and osteosarcoma).
    Type: Application
    Filed: December 3, 2018
    Publication date: June 6, 2019
    Inventors: Sheeno THYPARAMBIL, Dongyao YAN, Shankar SELLAPPAN, Fabiola CECCHI, Todd HEMBROUGH, Yeoun Jin KIM, Andrew CHAMBERS
  • Colon disease targets and uses thereof
    Patent number: 7776555
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: August 17, 2010
    Assignee: Celera Corporation
    Inventors: Bruno Domon, Steve Ruben, Charles E. Birse, Yeoun Jin Kim, Tao He, Ian McCaffery
  • Kidney disease targets and uses thereof
    Patent number: 7611703
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: November 3, 2009
    Assignee: Celera Corporation
    Inventors: Elizabeth G. Joseloff, Yeoun Jin Kim, Tao He, Steve Ruben